Nuzenio

Arrowhead Pharmaceuticals Acquires

Arrowhead Pharmaceuticals Acquires news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 3 publisher sources 100/100 entity strength

Latest news

ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 13:38:00 GMTArrowhead acquires FDA priority review voucher for plozasiran's severe hypertriglyceridemia expansion - AllSciAllSci · Wed, 05 Aug 2026 09:58:01 GMTArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Business WireBusiness Wire · Tue, 04 Aug 2026 20:01:00 GMTArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMT

Timeline

Wed, 05 Aug 2026 13:38:00 GMTARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG - Yahoo Finance
Wed, 05 Aug 2026 09:58:01 GMTArrowhead acquires FDA priority review voucher for plozasiran's severe hypertriglyceridemia expansion - AllSci
Tue, 04 Aug 2026 20:01:00 GMTArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Business Wire
Mon, 27 Jul 2026 07:00:00 GMTArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Yahoo Finance

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Arrowhead Pharmaceuticals Acquires.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.